首页> 外文期刊>BMC Immunology >In vitro evidence of efficacy and safety of a polymerized cat dander extract for allergen immunotherapy
【24h】

In vitro evidence of efficacy and safety of a polymerized cat dander extract for allergen immunotherapy

机译:聚合猫皮屑提取物对过敏原免疫治疗的功效和安全性的体外证据

获取原文
           

摘要

Background Allergy to cat epithelia is highly prevalent, being the major recommendation for allergy sufferers its avoidance. However, this is not always feasible. Allergen specific immunotherapy is therefore recommended for these patients. The use of polymerized allergen extracts, allergoids, would allow to achieve the high allergen doses suggested to be effective while maintaining safety. Results Cat native extract and its depigmented allergoid were manufactured and biochemically and immunochemically characterized. Protein and chromatographic profiles showed significant modification of the depigmented allergoid with respect to its corresponding native extract. However, the presence of different allergens (Fel d 1, Fel d 2, Fel d 3, Fel d 4 and Fel d 7) was confirmed in the allergoid. Differences in IgE-binding capacity were observed as loss of biological potency and lower stability of the IgE-allergen complex on surface plasmon resonance. The allergoid induced production of IgG antibodies able to block IgE-binding to native extract. Finally, studies carried out with peripheral-blood mononuclear cells from cat allergic patients showed that the allergoid induced IFN-γ and IL-10 production similar to that induced by native extract. Conclusions Cat depigmented allergoid induced production of cytokines involved in a Th1 and Treg response, was able to induce production of IgG-antibodies that blocks IgE-binding to cat native extract, and showed reduced interaction with IgE, suggesting greater safety than native extract while maintaining in vitro efficacy.
机译:背景技术对猫上皮的过敏症非常普遍,是避免过敏的主要建议。但是,这并不总是可行的。因此,建议对这些患者使用过敏原特异性免疫疗法。聚合的过敏原提取物,过敏原的使用将使建议的高过敏原剂量有效,同时保持安全性。结果猫天然提取物及其色素脱敏变体经制备,生化和免疫化学鉴定。蛋白质和色谱图谱显示,相对于其相应的天然提取物,色素沉着的变态反应动物的显着修饰。但是,在变应原中确认存在不同的过敏原(Fel d 1,Fel d 2,Fel d 3,Fel d 4和Fel d 7)。观察到IgE结合能力的差异是生物效能的丧失以及IgE-过敏原复合物在表面等离子体共振上的较低稳定性。变应原诱导的IgG抗体的产生能够阻断IgE与天然提取物的结合。最后,对来自猫过敏患者的外周血单个核细胞进行的研究表明,变应原诱导的IFN-γ和IL-10产生与天然提取物诱导的类似。结论:猫脱色素变态反应诱导的Th1和Treg反应涉及的细胞因子的产生,能够诱导IgG抗体的产生,该抗体阻断IgE与猫天然提取物的结合,并减少与IgE的相互作用,表明与天然提取物相比,安全性更高,同时保持体外功效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号